SHAKTI: Biologics Innovation Sans Animals

Biopharma SHAKTI Driving Biologics Innovation Beyond Animal Testing

Syllabus:

GS-3: Growth & Development, Mobilization of Resources

Why in the News ?

The Union Budget 2026 introduced Biopharma SHAKTI to strengthen India’s biologics ecosystem. The move gains importance amid growing concerns over limitations of animal testing and the global shift toward non-animal methodologies (NAMs) like organoids and organ-on-chip, which promise safer, faster, and cost-effective drug development.

Understanding Biologics and Their Growing Importance:

• Biologics Defined: These are large, complex molecules derived from living cells, unlike chemically synthesised drugs.
• Examples Include: Monoclonal antibodies (mAbs), vaccines, insulin, and gene therapies.
• Rising Demand: Increasing prevalence of chronic diseases like cancer, diabetes, and autoimmune disorders is driving global demand.
• Precision Medicine: Biologics offer target-specific treatments, improving therapeutic outcomes and reducing side effects.
• Economic Potential: Biologics represent one of the fastest-growing segments of the pharmaceutical industry, with high-value exports and innovation opportunities.

Limitations of Animal Testing in Biologics Development

• Species Differences: Animal immune systems often differ from humans, leading to inaccurate predictions of drug response.
• Northwick Park Tragedy (2006): The drug Theralizumab caused severe immune reactions in humans despite being safe in rhesus monkeys.
• Failure of Clinical Translation: Drugs like Semorinemab failed in human trials despite success in mouse models.
• Receptor Variability: Biologics bind to specific human receptors, which may be absent or function differently in animals.
• Ethical Concerns: Increasing global pressure to reduce animal experimentation due to ethical and welfare considerations.

Emergence of Non-Animal Methodologies (NAMs)

• Definition: NAMs refer to human-relevant models that replace or reduce animal testing.
• Key Technologies:
  • Organoids: Miniature organ-like structures derived from human stem cells.
  • Organ-on-Chip: Microfluidic systems simulating organ functions.
  • 3D Bioprinting: Printing tissues using human cells.
• Human Relevance: These models replicate human physiology more accurately than animals.
• Global Trends: Countries like the K. are actively promoting NAMs through regulatory roadmaps.
• Indian Push: The New Drugs and Clinical Trials (Amendment) Rules 2023 encourage NAM adoption.

Advantages of NAMs in Drug Development

• Improved Predictability: Better simulation of human biology enhances drug safety assessment.
• Reduced Costs: Studies suggest 10–26% cost reduction in drug development.
• Faster Development: Lead optimisation timelines may reduce by ~19%, accelerating innovation.
• Personalised Medicine: Enables testing on patient-specific cells, advancing precision healthcare.
• Reduced Animal Use: Supports ethical science by minimizing animal experimentation.

Biopharma SHAKTI: A Strategic Intervention

• Budget Allocation: ₹10,000 crore outlay to boost biologics and biosimilars
• Focus Areas:
  • Strengthening domestic manufacturing
  • Promoting research & innovation
  • Encouraging start-ups and MSMEs
• Ecosystem Approach: Emphasis on building platform technologies, not just individual products.
• NAM Integration: Opportunity to mainstream human-relevant models in biologics research.
• Global Competitiveness: Aims to position India as a biopharma hub.

Biosimilars and Market Dynamics

• Definition: Biosimilars are generic versions of biologics developed after patent expiry.
• Affordability: They reduce costs, improving access to life-saving therapies.
• Patent Evergreening: Companies extend exclusivity through minor modifications (e.g., trastuzumab case).
• Regulatory Bottlenecks: Approval from CDSCO is required, but updated guidelines are still evolving.
• Financial Risks: High development costs and uncertain returns discourage investors.

Bridging Research and Industry Gap in India

• Academic Strength: Over 90 Indian labs are working on NAM technologies.
• Translation Gap: Limited conversion of research into industry-ready applications.
• Standardisation Issues: Lack of uniform protocols and validation frameworks.
• Entrepreneurial Challenges: Weak start-up ecosystem and limited investor awareness.
• Supply Chain Gaps: Need for indigenous development of biological inputs and infrastructure.

Challenges :

• Regulatory Uncertainty: Lack of fully operational guidelines for NAM validation creates hesitation among industry players.
• Limited Accessibility: NAM technologies require high-end infrastructure, making them less accessible than animal models.
• Funding Constraints: Despite budget allocation, sustained funding for long-term research and scaling remains uncertain.
• Skill Deficit: Shortage of trained professionals in bioengineering, microfluidics, and computational biology.
• Patent Barriers: Evergreening practices delay entry of biosimilars, affecting affordability.
• Industry Hesitation: Pharmaceutical companies prefer traditional methods due to regulatory familiarity and lower risk perception.
• Weak Industry-Academia Linkages: Research innovations fail to reach market due to lack of collaboration frameworks.
• Investor Awareness Gap: Investors lack understanding of biologics risks and timelines, limiting funding for start-ups.
• Supply Chain Dependence: Dependence on imported biotech equipment and reagents increases costs.
• Ethical and Legal Gaps: Need for clear policies balancing innovation, ethics, and patient safety.

Way Forward :

• Regulatory Clarity: Fast-track approval of NAM-inclusive biosimilar guidelines to build industry confidence.
• Infrastructure Development: Establish centres of excellence for organ-on-chip and bioprinting technologies.
• Public-Private Partnerships: Promote collaboration between academia, industry, and government agencies.
• Skill Development: Launch specialised programs in biopharma engineering and translational research.
• Funding Mechanisms: Ensure sustained and targeted funding for platform technologies, not just products.
• Standardisation: Develop globally accepted protocols and validation frameworks for NAMs.
• Promote Start-ups: Provide incentives, tax benefits, and incubation support to biotech start-ups.
• Awareness Campaigns: Educate investors about biologics potential and long-term returns.
• Strengthen Supply Chains: Encourage domestic manufacturing of biotech inputs and equipment.
• Global Collaboration: Partner with international institutions to adopt best practices in NAMs.

Conclusion:

The Biopharma SHAKTI initiative marks a transformative step toward modernising India’s pharmaceutical sector. By integrating non-animal methodologies, addressing regulatory gaps, and fostering innovation, India can enhance drug safety, reduce costs, and emerge as a global leader in biologics and biosimilars, ensuring accessible and ethical healthcare solutions.

Source: HT

Mains Practice Question :

“Biologics represent the future of medicine, but their development challenges traditional testing models.” Discuss the role of Biopharma SHAKTI in promoting non-animal methodologies and strengthening India’s biologics ecosystem. Highlight associated challenges and suggest measures to enhance regulatory and industrial adoption.